- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT07558044
Ketamine Gargle for Pain After Pediatric Tonsillectomy (KET-TONSIL)
Preemptive Topical Ketamine for Post-Tonsillectomy Analgesia: A Randomized, Double-Blind, Placebo-Controlled Trial in Children
Post-tonsillectomy pain in children is a common and clinically significant problem that may lead to poor oral intake, dehydration, and delayed recovery. This study evaluates whether a simple preoperative intervention-gargling with ketamine-can reduce postoperative pain and improve recovery after pediatric adenotonsillectomy.
In this randomized, double-blind, placebo-controlled trial, 420 children aged 4 to 12 years undergoing elective adenotonsillectomy were assigned to receive either a ketamine gargle (40 mg in saline) or a saline placebo prior to anesthesia induction. Pain intensity was measured using the Visual Analog Scale at multiple time points within the first 24 hours after surgery. Secondary outcomes included postoperative bleeding requiring reintervention, analgesic consumption, and adverse events.
The study aims to determine whether topical ketamine provides effective and safe analgesia as part of an opioid-sparing strategy in pediatric airway surgery.
Studieöversikt
Status
Betingelser
Intervention / Behandling
Detaljerad beskrivning
Adenotonsillectomy is one of the most frequently performed surgical procedures in pediatric patients and is associated with significant postoperative pain. Effective analgesia remains challenging due to the need to balance efficacy with safety, particularly avoiding opioid-related respiratory complications. Topical ketamine, a non-competitive NMDA receptor antagonist, has been proposed as a peripheral analgesic strategy capable of reducing nociceptive signaling without significant systemic effects.
This study was designed as a prospective, randomized, double-blind, placebo-controlled trial conducted at a tertiary care center. A total of 420 pediatric patients (ASA I-II, aged 4-12 years) scheduled for elective adenotonsillectomy were enrolled. Participants were randomized in a 1:1 ratio to receive either a ketamine gargle (40 mg diluted in 30 mL saline) or a placebo saline gargle administered 5 minutes before induction of anesthesia.
All patients underwent standardized anesthetic and surgical protocols to minimize confounding variables. Pain intensity was assessed using the Visual Analog Scale at 0, 4, 8, 12, and 24 hours postoperatively. Secondary outcomes included incidence of postoperative hemorrhage requiring surgical reintervention, total rescue analgesic consumption, and adverse events such as nausea, vomiting, sedation, or psychomimetic effects.
The primary objective was to evaluate the analgesic efficacy of preemptive topical ketamine. Secondary analyses explored its potential impact on postoperative morbidity, particularly bleeding events. This study was conducted in accordance with ethical standards and CONSORT guidelines.
Studietyp
Inskrivning (Faktisk)
Fas
- Fas 4
Kontakter och platser
Studieorter
-
-
Miranda
-
Caracas, Miranda, Venezuela, 1040
- VERAZA
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
- Barn
Tar emot friska volontärer
Beskrivning
Inclusion Criteria:
- Children aged 4-12 years
- ASA physical status I-II
- Scheduled for elective adenotonsillectomy
- Ability to gargle and spit the study solution
Exclusion Criteria:
- Known hypersensitivity to ketamine
- Coagulation disorders
- History of neuropsychiatric disease
- Active upper respiratory tract infection
Exclusion Criteria:
-
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Fyrdubbla
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: KETAMINE GROUP
Preoperative gargle with 40 mg ketamine diluted in 30 mL saline, administered 5 minutes before induction of anesthesia.
|
Ketamine gargle at a dose of 40mg diluted in 30 mL of normal saline, administered 5 minutes before induction of anesthesia.
Patients were instructed to gargle the solution for 30 seconds and then expectorate.
Placebo gargle consisting of 30 mL of normal saline, administered 5 minutes before induction of anesthesia.
Patients were instructed to gargle the solution for 30 seconds and then expectorate.
|
|
Experimentell: PLACEBO GROUP
Preoperative gargle with 30 mL normal saline administered 5 minutes before induction.
|
Ketamine gargle at a dose of 40mg diluted in 30 mL of normal saline, administered 5 minutes before induction of anesthesia.
Patients were instructed to gargle the solution for 30 seconds and then expectorate.
Placebo gargle consisting of 30 mL of normal saline, administered 5 minutes before induction of anesthesia.
Patients were instructed to gargle the solution for 30 seconds and then expectorate.
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Postoperative pain intensity
Tidsram: 0, 4, 8, 12, and 24 hours postoperatively
|
Pain intensity measured using the Visual Analog Scale (VAS; 0-10) at predefined postoperative time points.
|
0, 4, 8, 12, and 24 hours postoperatively
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Postoperative hemorrhage requiring surgical reintervention
Tidsram: Within 24 hours postoperatively
|
Incidence of postoperative bleeding requiring return to the operating room for hemostasis.
|
Within 24 hours postoperatively
|
|
Rescue analgesic consumption
Tidsram: 24 hours postoperatively
|
Total requirement of additional analgesics (e.g., paracetamol or NSAIDs) within the first 24 hours after surgery.
|
24 hours postoperatively
|
|
Adverse events
Tidsram: 24 hours postoperatively
|
Incidence of postoperative nausea and vomiting, sedation, or psychomimetic effects such as hallucinations or dysphoria.
|
24 hours postoperatively
|
Samarbetspartners och utredare
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Faktisk)
Avslutad studie (Faktisk)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Nyckelord
Ytterligare relevanta MeSH-villkor
- Smärta
- Neurologiska manifestationer
- Postoperativa komplikationer
- Patologiska processer
- Patologiska tillstånd, tecken och symtom
- Tecken och symtom
- Smärta, postoperativt
- Organiska kemikalier
- Farmaceutiska förberedelser
- Kolväten
- Cyklohexaner
- Cykloparaffiner
- Kolväten, alicyklisk
- Kolväten, cykliska
- Oorganiska kemikalier
- Klorföreningar
- Kristalloidlösningar
- Isotonlösningar
- Lösningar
- Natriumföreningar
- Klorider
- Saltsyra
- Ketamin
- Saltlösning
- Natriumklorid
Andra studie-ID-nummer
- KET-AT-2024-01
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
IPD-planbeskrivning
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .